LIVDELZI®

Hold Company

GILEAD SCIENCES INC

Learn More

Dosage and Administration

CAPSULE;ORAL

Specification

EQ 10MG BASE

Indication

Livdelzi® is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

Use

Instructions for Use

API

SELADELPAR LYSINE

API Structure

We Supply

SELADELPAR

Drug Patent

Patent No	Expiration Date
10272058	2035/3/19
11406611	2035/3/19
11596614	2035/3/19
7301050	2025/8/2
7709682	2026/9/13
9486428	2035/3/19

API Patent

Patent No	Expiration Date
7301050	2025/8/2
7709682	2026/9/13

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.